Protective impact of resveratrol in experimental rat model of hyperoxaluria
- 216 Downloads
Abstract
Purpose
Resveratrol (RES) is a polyphenol with antioxidant, anti-inflammatory, and many other physiological effects on tissues. In the present study, the effect of resveratrol in hyperoxaluria driven nephrolithiasis/nephrocalcinosis is investigated.
Methods
Wistar-Albino rats of 250–300 g (male, n = 24) were included in the present study. The rats were randomized into three groups: Group 1 consisted of the controls (n = 8), Group 2 of hyperoxaluria (1% ethylene glycol (EG), n = 8), and Group 3 of the treatment (1% EG + 10 mg/kg of RES, n = 8) group. At the beginning and fifth week of the study, two rats from each group were placed in metabolic cages for 24 h and their urine was collected. At the end of the study, the rats were killed and their blood was collected from the vena cava inferior. The right kidneys of the rats were used for biochemical and the left ones for immunohistochemical analyzes. Malondialdehyde (MDA), catalase, urea, calcium, oxalate, and creatinine clearance were studied in the blood, urine, and kidney tissues. Moreover, routine histological evaluation, and p38-MAPK and NFkB immunohistochemical analyses were conducted.
Results
In the hyperoxaluria group, urinary oxalate levels were higher than the control group; yet, lower in the treatment group compared to hyperoxaluria group (p < 0.05). Serum MDA levels in the hyperoxaluria group were higher than the control group; but in the treatment group it is lower than the hyperoxaluria group (p < 0.05). P38 MAPK activity was higher in the hyperoxaluria group compared to the control (p < 0.05). However, in terms of p38 MAPK activity, there were no statistically significant difference between hyperoxaluria and the treatment group (p < 0.069). Whereas NFkB activity in the hyperoxaluria group is higher than the control (p < 0.001), no statistically significant difference was observed with the treatment group.
Conclusions
In the present study, resveratrol was seen to prevent hyperoxaluria. With preventing oxidative stress factors and Randall plaque formation caused by free oxygen radicals, resveratrol can be an alternative treatment option that can increase the success rate in preventing stone recurrence in the future.
Keywords
Calcium oxalate Ethylene glycol Hyperoxaluria Rat ResveratrolAbbreviations
- EG
Ethylene glycol
- RES
Resveratrol
- MDA
Malondialdehyde
- MAPK
Mitogen activated protein kinase
- NFkB
Nuclear factor kappa B
- CaOx
Calcium oxalate
- SOD
Superoxide dismutase
- ROS
Reactive oxygen species
- TBARS
Thiobarbituric acid reactive substance
- JNK
C-Jun N-terminal kinase
- AP-1
Active protein-1
- OPN
Osteopontin
- XO
Xanthine oxidase
- TNF
Tumor necrosis factor
- PKC
Protein kinase C
- SPSS 11.0
Statistical Package for Social Sciences 11.0
- CAT
Catalase
- ESWL
Extra shock wave lithotripsy
Notes
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interests.
Ethical approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. The study design was approved by the Süleyman Demirel University Animal Experiments Local Ethic Board, Turkey.
References
- 1.Gambaro G, Vezzol G, Casari G, Rampoldi L, Angelo AD, Borghi L (2004) Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 44:963–986CrossRefPubMedGoogle Scholar
- 2.Coe FL, Parks JH, Asplin JH (1992) The pathogenesis and treatment of kidney stones. N Engl J Med 327:1141–1152CrossRefPubMedGoogle Scholar
- 3.Tiselius HG (2000) Stone incidence and prevention. Braz J Urol 2000(26):452–462Google Scholar
- 4.Jonassen JA, Kohjimoto Y, Scheid CR, Schmidt M (2005) Oxalate toxicity in renal cells. Urol Res 33:329–339CrossRefPubMedGoogle Scholar
- 5.Park S, Pearle MS (2007) Pathophysiology and management of calcium stones. Urol Clin North Am 34:323–334CrossRefPubMedGoogle Scholar
- 6.Hess B, Ryall RL, Kavanagh JP et al (2001) Methods for measuring crystallization in urolithiasis research: why, how and when? Eur Urol 40:220–230CrossRefPubMedGoogle Scholar
- 7.Menon M, Koul H (1992) Clinical review 32: calcium oxalate nephrolithiasis. J Clin Endocrinol Metab 74:703–710CrossRefPubMedGoogle Scholar
- 8.Peterson J, Dwyer J (1998) Flavonoids: dietary occurrence and biochecmical activity. Nutr Res 18:1995–2018CrossRefGoogle Scholar
- 9.Nijveldt RJ, Nood E, Hoorn OEC, Boelens PG, Noreen K, Leeuwen PAM (2001) Flavonoids: a review of probable mechanism of action and potential applications. Clin Nutr 74:418–425Google Scholar
- 10.Elliott M, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673–751Google Scholar
- 11.Schroeter H, Spencer JPE, Rice-Evans C (2003) Current status of the potential role of flavonoids in neuroprotection. In: Cutler RG, Rodriguez H (eds) Critical reviews of oxidative stress and aging: advances in basic science, diagnostics and intervent, vol I. World Scientific Publisher, Singapore, p 137Google Scholar
- 12.Wang S, Meng Q, Xie Q, Zhang M (2017) Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells. Mol Med Rep. doi: 10.3892/mmr.2017.6111 Google Scholar
- 13.Huang H-S, Ma M-C, Chen C-F, Chen J (2003) Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 61:1123CrossRefGoogle Scholar
- 14.Holoch PA, Tracy C (2011) Antioxidants and self-reported history of kidney stones: the National Health and Nutrition Examination Survey. J Endourol 25:1903CrossRefPubMedGoogle Scholar
- 15.Khan SR (2013) Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol 189(3):803–811CrossRefPubMedGoogle Scholar
- 16.Khan SR (2004) Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue culture studies. Clin Exp Nephrol 8:75CrossRefPubMedGoogle Scholar
- 17.Ladwig PM, Liedtke RR, Larson TS, Lieske JC (2005) Sensitive spectrophotometric assay for plasma oxalate. Clin Chem 51:2377–2380CrossRefPubMedGoogle Scholar
- 18.Aebi H (1974) Catalase. In: Bergmeyer HU (ed) Method of enzymatic analysis, 2nd edn. Academic Press, New York, pp 673–684CrossRefGoogle Scholar
- 19.Lowry O, Rosebrough N, Farr L, Randall R (1951) Protein measurement with the folin–phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
- 20.Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358CrossRefPubMedGoogle Scholar
- 21.Koul H, Kenington L, Nair G, Honeyman T (1994) Oxalate induced initiation of DNA synthesis in LLC-PK1 cells, a line of renal epithelial cells. Biochem Biology Res Comm 205:1632CrossRefGoogle Scholar
- 22.Khan SR (2005) Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 33:349–357CrossRefPubMedGoogle Scholar
- 23.Jeong BC, Kim BS, Kim JI, Kim HH (2006) Effects of green tea on urinary stone formation: an in vivo and in vitro study. J Endourol 20(5):356–361CrossRefPubMedGoogle Scholar
- 24.Itoh Y, Yasui T, Okada A et al (2005) Preventive effects of green tea on renal stone formation and the role of oxidative stress in nephrolithiasis. J Urol 173(1):271–275CrossRefPubMedGoogle Scholar
- 25.Park HK, Jeong BC, Sung MK, Park MY et al (2008) Reduction of oxidative stress in cultured renal tubular cells and preventive effects on renal stone formation by the bioflavonoid quercetin. J Urol 179(4):1620–1626CrossRefPubMedGoogle Scholar
- 26.Aggarwal D, Gautam D, Sharma M, Singla SK (2016) Bergenin attenuates renal injury by reversing mitochondrial dysfunction in ethylene glycol induced hyperoxaluric rat model. Eur J Pharmacol 791:611–621CrossRefPubMedGoogle Scholar
- 27.Khan SR (2004) Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue culture studies. Clin Exp Nephrol 8:75CrossRefPubMedGoogle Scholar
- 28.Khan SR (2004) Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol 98:55CrossRefGoogle Scholar
- 29.Scheid CR, Koul H, Hill WA, Luber-Narod J, Kennington L, Honeyman T, Jonassen J, Menon M (1996) Oxalate toxicity in LLCPK1 cells: role of free radicals. Kidney Int 49:413CrossRefPubMedGoogle Scholar
- 30.Thamilselvan S, Hackett RL, Khan SR (1997) Lipid peroxidation in ethylene glycol induced hyperoxaluria and CaOx nephrolithiasis. J Urol 157:1059CrossRefPubMedGoogle Scholar
- 31.Sharma M, Kaur T, Singla SK (2016) Role of mitochondria and NADPH oxidase derived reactive oxygen species in hyperoxaluria induced nephrolithiasis: therapeutic intervention with combinatorial therapy of N-acetyl cysteine and Apocynin. Mitochondrion 27:15–24CrossRefPubMedGoogle Scholar
- 32.Marangella M, Vitale C, Bagnis C, Bruno M, Ramello A (1999) Idiopathic calcium nephrolithiasis. Nephron 8:38–44Google Scholar
- 33.Laminski NA, Meyers AM, Kruger M et al (1991) Hyperoxaluria in patients with recurrent calcium oxalate calculi: dietary and other risk factors. J Urol 68(5):454–458CrossRefGoogle Scholar
- 34.Murray RK, Granner DK, Mayes PA, Rodwell VW (1990) Harper’s biochemistry, 2nd edn. Appleton and Lange, NorwalkGoogle Scholar
- 35.Khan SR, Kok DJ (2004) Modulators of urinary stone formation. Front Biosci 9:1450CrossRefPubMedGoogle Scholar
- 36.Khachigian LM, Collins T, Fries JW (1997) N-acetyl cysteine blocks mesangial VCAM-1 and NF-kappa B expression in vivo. Am J Pathol 151:1225–1229PubMedPubMedCentralGoogle Scholar
- 37.Ruiz-Ortega M, Bustos C, Hernández-Presa MA et al (1998) Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factorkappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161:430–439PubMedGoogle Scholar
- 38.Goligorsky MS, Brodsky SV, Noiri E (2002) Nitric oxide in acute renal failure: NOS versus NOS. Kidney Int 61:855–861CrossRefPubMedGoogle Scholar
- 39.Kumar S, Boehm J, Lee JC (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2:717–726CrossRefPubMedGoogle Scholar
- 40.Stambe C, Atkins RC, Tesch GH et al (2003) Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol 14(2):338–351CrossRefPubMedGoogle Scholar
- 41.Donnahoo KK, Shames BD, Harken AH et al (1999) Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 162(51):196–203CrossRefPubMedGoogle Scholar
- 42.Polat A, Parlakpınar H, Tasdemir S et al (2006) Protective role of aminoguanidine on gentamicin-induced acute renal failure in rats. Acta Histochem 108:365–371CrossRefPubMedGoogle Scholar
- 43.Juan SH, Chen CH, Hsu YH et al (2007) Tetramethylpyrazine protectsrat renal tubular cell apoptosis induced by gentamicin. Nephrol Dial Transplant 22:732–739CrossRefPubMedGoogle Scholar